Lates News

On the morning of August 20th, Hutchison Pharma and Walrysha Pharmaceuticals announced on the Hong Kong Stock Exchange that the SANOVO China Phase III study for the combination therapy of Walrysha and Terisha for first-line treatment of specific non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations and MET overexpression has completed patient enrollment. The last patient for the study was enrolled on August 18th, 2025. The top-line results of the SANOVO study are expected to be announced in the second half of 2026 and will be submitted for publication at an appropriate academic conference shortly thereafter. If the desired results are achieved, Hutchison Pharma and Walrysha will initiate plans to submit a new indication application to the National Medical Products Administration.